Investigational drug · Phase 2
PEX010-Assisted Therapy
Also called: PEX010
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Stimulant Use Disorder, Opioid Use Disorder.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 30, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
13
Any phase or sponsor naming "PEX010-Assisted Therapy"
First trial start
2024
Dec 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PEX010-Assisted Therapy", any sponsor or status.
- Phase 211
Conditions studied
As listed on its trial records.
- Stimulant Use Disorder
- Opioid Use Disorder
Approved drugs for the same conditions: Opioid use disorder · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "PEX010-Assisted Therapy" as an intervention, largest first.
University Hospital, GhentAcademic, hospital or other
NCT06378229 · 100 participants (planned) · Start May 21, 2024 · Primary completion Mar 2026
Drug: Psilocybin · For: Treatment Resistant Depression
Sites: Ghent, Belgium
- PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy StudyNot yet recruiting
Filament Health Corp.Industry
NCT06666010 · 86 participants (planned) · Start Jan 2025 · Primary completion Jan 2028
Drug: PEX010-Assisted Therapy; PEX010(01) · For: Stimulant Use Disorder
- Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner ViolenceNot yet recruiting
University of CalgaryAcademic, hospital or other
NCT06885996 · 76 participants (planned) · Start Oct 1, 2026 · Primary completion Aug 1, 2028
Drug: Psilocybin · For: Post Traumatic Stress Disorder PTSD; Intimate Partner Violence (IPV)
Sites: Calgary, Canada; Kelowna, Canada
- MB-PAT for Demoralization in Advanced Cancer ('PAT-MIND') TrialNot yet recruiting
University of CalgaryAcademic, hospital or other
NCT07791901 · 60 participants (planned) · Start Oct 30, 2026 · Primary completion Dec 20, 2027
Drug: PEX010 25 mg psilocybin; PEX010 5 mg psilocybin · For: Advanced Cancer; Demoralization; Existential Distress and 1 more
Sites: Calgary, Canada; Kingston, Canada
University of CalgaryAcademic, hospital or other
NCT06615908 · 40 participants (planned) · Start May 27, 2025 · Primary completion Jun 30, 2027
Drug: Psilocybin · For: Persisting Symptoms After Concussion
Sites: Calgary, Canada
- Psychedelic-assisted Group Program for First RespondersStatus unknown
Empower Research IncIndustry
NCT06471959 · 32 participants (planned) · Start Jan 1, 2025 · Primary completion Jul 1, 2025
Drug: Psilocybin · For: Psilocybin; Psychotherapy, Group
Sites: Surrey, Canada
Nantes University HospitalAcademic, hospital or other
NCT07391332 · 30 participants (planned) · Start Oct 8, 2026 · Primary completion Jul 8, 2029
Drug: Psychotherapy assisted by high-dose psilocybin (25mg or 40mg where appropriate); Psychotherapy assisted by low-dose psilocybin (1 mg) · For: Gambling Disorder
Sites: Nantes, France
Nicky Mehtani, MD, MPHAcademic, hospital or other
NCT07756736 · 30 participants (planned) · Start Dec 2026 · Primary completion Apr 2029
Drug: Psilocybin 5 mg; Psilocybin 25 mg · For: Methamphetamine Use Disorder; Human Immunodeficiency Virus (HIV)
Sites: San Francisco, California
- Understanding Music and Mindfulness Preferences in Psilocybin-Assisted PsychotherapyNot yet recruiting
Kyle GreenwayAcademic, hospital or other
NCT07373535 · 16 participants (planned) · Start Dec 2026 · Primary completion Dec 2028
Drug: Psilocybin 25mg · For: Treatment-Resistant Major Depressive Disorder
Sites: Montreal, Canada · 2 sites in all
Centre for Addiction and Mental HealthAcademic, hospital or other
NCT06299319 · 10 participants · Start Sep 1, 2024 · Primary completion Sep 4, 2026
Drug: Psilocybin · For: Obsessive-Compulsive Disorder
Sites: Toronto, Canada
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.